Wildtype Kras2 can inhibit lung carcinogenesis in mice - PubMed (original) (raw)
Y Wang, H G Vikis, L Johnson, G Liu, J Li, M W Anderson, R C Sills, H L Hong, T R Devereux, T Jacks, K L Guan, M You
Affiliations
- PMID: 11528387
- DOI: 10.1038/ng721
Wildtype Kras2 can inhibit lung carcinogenesis in mice
Z Zhang et al. Nat Genet. 2001 Sep.
Abstract
Although the ras genes have long been established as proto-oncogenes, the dominant role of activated ras in cell transformation has been questioned. Previous studies have shown frequent loss of the wildtype Kras2 allele in both mouse and human lung adenocarcinomas. To address the possible tumor suppressor role of wildtype Kras2 in lung tumorigenesis, we have carried out a lung tumor bioassay in heterozygous Kras2-deficient mice. Mice with a heterozygous Kras2 deficiency were highly susceptible to the chemical induction of lung tumors when compared to wildtype mice. Activating Kras2 mutations were detected in all chemically induced lung tumors obtained from both wildtype and heterozygous Kras2-deficient mice. Furthermore, wildtype Kras2 inhibited colony formation and tumor development by transformed NIH/3T3 cells and a mouse lung tumor cell line containing an activated Kras2 allele. Allelic loss of wildtype Kras2 was found in 67% to 100% of chemically induced mouse lung adenocarcinomas that harbor a mutant Kras2 allele. Finally, an inverse correlation between the level of wildtype Kras2 expression and extracellular signal-regulated kinase (ERK) activity was observed in these cells. These data strongly suggest that wildtype Kras2 has tumor suppressor activity and is frequently lost during lung tumor progression.
Similar articles
- LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer.
Li J, Zhang Z, Dai Z, Plass C, Morrison C, Wang Y, Wiest JS, Anderson MW, You M. Li J, et al. Oncogene. 2003 Feb 27;22(8):1243-6. doi: 10.1038/sj.onc.1206192. Oncogene. 2003. PMID: 12606951 Free PMC article. - A new verdict for an old convict.
Pfeifer GP. Pfeifer GP. Nat Genet. 2001 Sep;29(1):3-4. doi: 10.1038/ng0901-3. Nat Genet. 2001. PMID: 11528376 - Isoform-specific ras activation and oncogene dependence during MYC- and Wnt-induced mammary tumorigenesis.
Jang JW, Boxer RB, Chodosh LA. Jang JW, et al. Mol Cell Biol. 2006 Nov;26(21):8109-21. doi: 10.1128/MCB.00404-06. Epub 2006 Aug 14. Mol Cell Biol. 2006. PMID: 16908535 Free PMC article. - The Kras2 oncogene and mouse lung carcinogenesis.
Lee GH. Lee GH. Med Mol Morphol. 2008 Dec;41(4):199-203. doi: 10.1007/s00795-008-0419-6. Epub 2008 Dec 24. Med Mol Morphol. 2008. PMID: 19107609 Review. - Role of oncogenes and tumour suppressor genes in human lung carcinogenesis.
Harris CC, Reddel R, Pfeifer A, Iman D, McMenamin M, Trump BF, Weston A. Harris CC, et al. IARC Sci Publ. 1991;(105):294-304. IARC Sci Publ. 1991. PMID: 1855868 Review.
Cited by
- Loss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis.
Kong G, Chang YI, Damnernsawad A, You X, Du J, Ranheim EA, Lee W, Ryu MJ, Zhou Y, Xing Y, Chang Q, Burd CE, Zhang J. Kong G, et al. Leukemia. 2016 Jul;30(7):1542-51. doi: 10.1038/leu.2016.40. Epub 2016 Feb 29. Leukemia. 2016. PMID: 27055865 Free PMC article. - Mutant allele specific imbalance in oncogenes with copy number alterations: Occurrence, mechanisms, and potential clinical implications.
Yu CC, Qiu W, Juang CS, Mansukhani MM, Halmos B, Su GH. Yu CC, et al. Cancer Lett. 2017 Jan 1;384:86-93. doi: 10.1016/j.canlet.2016.10.013. Epub 2016 Oct 8. Cancer Lett. 2017. PMID: 27725226 Free PMC article. Review. - Mouse pulmonary adenoma susceptibility 1 locus is an expression QTL modulating Kras-4A.
Dassano A, Colombo F, Trincucci G, Frullanti E, Galvan A, Pettinicchio A, De Cecco L, Borrego A, Martinez Ibañez OC, Dragani TA, Manenti G. Dassano A, et al. PLoS Genet. 2014 Apr 17;10(4):e1004307. doi: 10.1371/journal.pgen.1004307. eCollection 2014 Apr. PLoS Genet. 2014. PMID: 24743582 Free PMC article. - KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer.
Burgess MR, Hwang E, Mroue R, Bielski CM, Wandler AM, Huang BJ, Firestone AJ, Young A, Lacap JA, Crocker L, Asthana S, Davis EM, Xu J, Akagi K, Le Beau MM, Li Q, Haley B, Stokoe D, Sampath D, Taylor BS, Evangelista M, Shannon K. Burgess MR, et al. Cell. 2017 Feb 23;168(5):817-829.e15. doi: 10.1016/j.cell.2017.01.020. Epub 2017 Feb 16. Cell. 2017. PMID: 28215705 Free PMC article. - Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.
Xu J, Haigis KM, Firestone AJ, McNerney ME, Li Q, Davis E, Chen SC, Nakitandwe J, Downing J, Jacks T, Le Beau MM, Shannon K. Xu J, et al. Cancer Discov. 2013 Sep;3(9):993-1001. doi: 10.1158/2159-8290.CD-13-0096. Epub 2013 Jun 3. Cancer Discov. 2013. PMID: 23733505 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous